ES2654177T3 - Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer - Google Patents

Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer Download PDF

Info

Publication number
ES2654177T3
ES2654177T3 ES15192658.1T ES15192658T ES2654177T3 ES 2654177 T3 ES2654177 T3 ES 2654177T3 ES 15192658 T ES15192658 T ES 15192658T ES 2654177 T3 ES2654177 T3 ES 2654177T3
Authority
ES
Spain
Prior art keywords
mmol
mixture
methoxy
ch2cl2
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15192658.1T
Other languages
English (en)
Spanish (es)
Inventor
Sam Butterworth
Maurice Raymond Verschoyle Finlay
Richard Andrew Ward
Vasantha Krishna Kadambar
Chandrasekhara Reddy Chintakuntla
Andiappan Murugan
Claudio Edmundo Chuaqui
Heather Marie Redfearn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2654177(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2654177T3 publication Critical patent/ES2654177T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
ES15192658.1T 2011-07-27 2012-07-25 Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer Active ES2654177T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161512061P 2011-07-27 2011-07-27
US201161512061P 2011-07-27
US201261591363P 2012-01-27 2012-01-27
US201261591363P 2012-01-27

Publications (1)

Publication Number Publication Date
ES2654177T3 true ES2654177T3 (es) 2018-02-12

Family

ID=46875901

Family Applications (5)

Application Number Title Priority Date Filing Date
ES20157798T Active ES2914854T3 (es) 2011-07-27 2012-07-25 Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
ES12759801.9T Active ES2564671T3 (es) 2011-07-27 2012-07-25 Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
ES20157927T Active ES2900230T3 (es) 2011-07-27 2012-07-25 Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
ES15192658.1T Active ES2654177T3 (es) 2011-07-27 2012-07-25 Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer
ES17194307T Active ES2791308T3 (es) 2011-07-27 2012-07-25 Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES20157798T Active ES2914854T3 (es) 2011-07-27 2012-07-25 Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
ES12759801.9T Active ES2564671T3 (es) 2011-07-27 2012-07-25 Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
ES20157927T Active ES2900230T3 (es) 2011-07-27 2012-07-25 Compuestos de 2-(2,4,5-anilino sustituido)pirimidina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17194307T Active ES2791308T3 (es) 2011-07-27 2012-07-25 Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer

Country Status (38)

Country Link
US (8) US8946235B2 (enExample)
EP (7) EP3009431B1 (enExample)
JP (3) JP5427321B2 (enExample)
KR (3) KR101410902B1 (enExample)
CN (7) CN103702990B (enExample)
AR (1) AR087336A1 (enExample)
AU (1) AU2012288626C1 (enExample)
BR (4) BR122014026094B1 (enExample)
CA (5) CA2881993C (enExample)
CL (1) CL2013003281A1 (enExample)
CO (1) CO6811863A2 (enExample)
CR (1) CR20130629A (enExample)
CY (4) CY1117431T1 (enExample)
DK (5) DK3686194T3 (enExample)
DO (1) DOP2013000263A (enExample)
EA (3) EA033733B1 (enExample)
EC (1) ECSP13013033A (enExample)
ES (5) ES2914854T3 (enExample)
GT (1) GT201300288A (enExample)
HR (4) HRP20160135T1 (enExample)
HU (4) HUE026429T2 (enExample)
IL (6) IL229199A (enExample)
LT (3) LT3333161T (enExample)
ME (3) ME02382B (enExample)
MX (3) MX377900B (enExample)
MY (2) MY194532A (enExample)
NI (1) NI201300134A (enExample)
PE (1) PE20141700A1 (enExample)
PH (2) PH12013502312A1 (enExample)
PL (5) PL3333161T3 (enExample)
PT (4) PT3333161T (enExample)
RS (4) RS60190B1 (enExample)
SG (5) SG10201910984XA (enExample)
SI (4) SI3009431T1 (enExample)
SM (3) SMT202100652T1 (enExample)
TW (3) TWI583386B (enExample)
UY (1) UY34219A (enExample)
WO (1) WO2013014448A1 (enExample)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PL2300013T5 (pl) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
IN2012DN01325A (enExample) 2009-08-20 2015-06-05 Karus Therapeutics Ltd
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
DK3686194T3 (da) 2011-07-27 2021-11-22 Astrazeneca Ab 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
ES2935352T3 (es) 2013-01-29 2023-03-06 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
MX375286B (es) * 2013-01-29 2025-03-06 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
ES2761406T3 (es) 2013-03-15 2020-05-19 G1 Therapeutics Inc Protección transitoria de células normales durante una quimioterapia
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014210354A1 (en) * 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
CN104292142B (zh) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 一种n-芳基杂环丁烷脱芳基方法
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
RS59140B1 (sr) * 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilna jedinjenja kao inhibitori btk i njihova upotreba
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3125885B1 (en) * 2014-04-04 2021-06-30 Astrazeneca AB Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
US20170166598A1 (en) * 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN111892579B (zh) * 2014-06-12 2023-07-25 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
SMT201900142T1 (it) * 2014-06-19 2019-05-10 Ariad Pharma Inc Composti eteroarilici per inibizione di chinasi
CN105254615B (zh) * 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN105315285B (zh) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
CN105315259B (zh) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN104140418B (zh) * 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
CN113121575A (zh) * 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN104356040A (zh) * 2014-09-17 2015-02-18 爱斯特（成都）生物制药有限公司 一种1-二苯甲基-3-羟基氮杂环丁烷盐酸盐的制备方法
CN105461695B (zh) * 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN105524068B (zh) * 2014-09-30 2017-11-24 上海海雁医药科技有限公司 氮杂双环衍生物、其制法与医药上的用途
CN105237515B (zh) * 2014-10-10 2018-06-05 益方生物科技（上海）有限公司 氘代嘧啶类化合物、其制备方法、药物组合物和用途
CN117069700A (zh) * 2014-10-11 2023-11-17 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
PT3604294T (pt) * 2014-10-13 2021-07-29 Yuhan Corp Compostos e composições para modular atividades da cinase do mutante de egfr
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
EP3226869A4 (en) * 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
CN112375067B (zh) * 2014-12-11 2024-03-15 贝达医药公司 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂
WO2016105525A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
CN104961731A (zh) * 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
CN107613769A (zh) 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
CN107973791B (zh) * 2015-04-29 2020-04-07 南京圣和药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
TWI687420B (zh) * 2015-04-29 2020-03-11 大陸商南京聖和藥業股份有限公司 稠環或三環芳基嘧啶化合物用作激酶抑制劑
CN104817541B (zh) * 2015-05-11 2017-06-16 苏州东南药业股份有限公司 一种抗肿瘤药物的合成方法
US20210323976A1 (en) * 2015-05-13 2021-10-21 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
HK1250638A1 (zh) 2015-05-15 2019-01-11 Novartis Ag 治疗egfr突变的癌症的方法
CN104910049B (zh) 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 Azd9291中间体及其制备方法
EP3323817B1 (en) * 2015-07-16 2022-10-19 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Aniline pyrimidine derivatives and uses thereof
EP3325469A4 (en) 2015-07-20 2019-01-23 Dana Farber Cancer Institute, Inc. NOVEL PYRIMIDINS AS EGFR INHIBITORS AND METHOD FOR THE DISEASE TREATMENT THEREWITH
CN107531678B (zh) * 2015-07-24 2020-12-22 上海海雁医药科技有限公司 Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
CN105001208A (zh) * 2015-08-06 2015-10-28 南京雷科星生物技术有限公司 一种表皮生长因子受体egfr抑制剂及其制备方法与用途
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
CN106117185B (zh) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
KR102051609B1 (ko) * 2015-08-31 2019-12-03 우시 상량 바이오테크놀로지 씨오., 엘티디. 2-아릴아미노피리딘, 피리미딘 또는 트리아진 유도체 및 그 제조방법과 사용
CN110483485A (zh) * 2015-09-02 2019-11-22 益方生物科技（上海）有限公司 嘧啶类化合物、其制备方法和医药用途
RU2603960C1 (ru) * 2015-11-19 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака
RU2606949C9 (ru) * 2015-11-19 2018-03-14 ЗАО "Р-Фарм" Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака
TW201718583A (zh) * 2015-11-23 2017-06-01 Nanjing Sanhome Pharmaceutical Co Ltd 新的表皮生長因子受體抑制劑及其應用
CN106810553B (zh) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
AU2016362390B2 (en) * 2015-12-03 2021-11-11 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
CA3007110C (en) * 2015-12-03 2025-07-08 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. HETEROCYCLIC COMPOUNDS AND THEIR USES
CN105601620A (zh) * 2015-12-25 2016-05-25 北京康立生医药技术开发有限公司 一种甲磺酸迈瑞替尼的制备方法
CN106928150B (zh) 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
US10435388B2 (en) 2016-01-07 2019-10-08 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
CN105646454B (zh) * 2016-01-19 2018-05-08 浙江大学 含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用
CN106995437A (zh) * 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
CN108610331A (zh) * 2016-01-22 2018-10-02 焦玉奇 2-(2,4,5-取代苯胺)嘧啶衍生物
TWI745345B (zh) * 2016-02-01 2021-11-11 瑞典商阿斯特捷利康公司 製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法
CN107043368B (zh) * 2016-02-05 2020-07-31 齐鲁制药有限公司 芳胺嘧啶化合物及其盐的结晶
CN107043369A (zh) * 2016-02-06 2017-08-15 焦玉奇 2‑(2,4,5‑取代苯胺)嘧啶衍生物
CN107098887B (zh) * 2016-02-22 2019-08-09 复旦大学 嘧啶类化合物
CN105646467B (zh) * 2016-02-25 2018-07-20 黄燕鸽 一种抗癌化合物奥美替尼及其合成方法
CN105585557B (zh) * 2016-02-25 2018-06-22 清华大学 用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
CN105777716B (zh) * 2016-02-25 2018-04-10 清华大学 一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
CN107163026B (zh) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物的盐及其制备方法和应用
CN110590749B (zh) 2016-03-07 2020-11-06 上海艾力斯医药科技股份有限公司 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
CN107188888A (zh) * 2016-03-15 2017-09-22 罗欣生物科技（上海）有限公司 一种制备甲磺酸迈瑞替尼的方法
CN108884072B (zh) 2016-03-22 2020-12-22 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用
EA201892311A1 (ru) * 2016-05-11 2019-06-28 Бета Фарма, Инк. Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
KR102128675B1 (ko) 2016-05-19 2020-06-30 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7030066B2 (ja) 2016-05-26 2022-03-04 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｅｇｆｒ阻害剤化合物
KR20190018494A (ko) * 2016-06-17 2019-02-22 베타 파마, 인크. N-(2-(2-(디메틸아미노)에톡시)-4-메톡시-5-((4-(1-메틸-1h-인돌-3-일)피리미딘-2-일)아미노)페닐)아크릴아미드의 제약 염 및 그의 결정질 형태
CN107522690B (zh) * 2016-06-20 2022-08-05 海南先声药业有限公司 一种Osimertinib的制备方法
CN107540661A (zh) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN107663207B (zh) * 2016-07-27 2021-07-30 南京圣和药业股份有限公司 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
CN107663208B (zh) * 2016-07-27 2021-10-15 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
CA3031563C (en) 2016-08-01 2023-12-05 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
JP7101165B2 (ja) 2016-08-15 2022-07-14 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
CN106366022B (zh) * 2016-08-19 2018-03-13 上海工程技术大学 一种用于制备azd9291的中间体及其制备方法和应用
CN106366072B (zh) * 2016-08-19 2018-12-07 上海工程技术大学 一种azd9291的制备方法
CN106397407B (zh) * 2016-08-31 2018-09-04 浙江科聚化工有限公司 抗肿瘤药物azd9291衍生物的制备方法
CN106432231B (zh) * 2016-09-09 2018-06-12 无锡佰翱得生物科学有限公司 Azd9291的药用盐、及其晶型和制备方法
JP6746794B2 (ja) * 2016-09-19 2020-08-26 南京創特医薬科技有限公司Ｎａｎｊｉｎｇ Ｃｈｕａｎｇｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ 重水素化３−（４，５−置換アミノピリミジン）フェニル誘導体及びその使用
CN107955019B (zh) * 2016-10-17 2021-09-14 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法
WO2018073839A1 (en) 2016-10-18 2018-04-26 Mylan Laboratories Limited Amorphous osimertinib mesylate, processes for its preparation and solid amorphous dispersions thereof
WO2018075823A1 (en) * 2016-10-19 2018-04-26 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
CN106496196B (zh) * 2016-10-20 2019-07-02 南京雷科星生物技术有限公司 一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
CN106543060B (zh) * 2016-10-31 2018-11-06 湖南欧亚药业有限公司 一种奥斯替尼甲磺酸盐的制备方法
CN108299419B (zh) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
SG11201906435SA (en) 2017-01-26 2019-08-27 Hanmi Pharmaceutical Co Ltd Pyrimidine compound and pharmaceutical use thereof
WO2018156812A1 (en) * 2017-02-22 2018-08-30 G1 Therapeutics, Inc. Treatment of egfr-driven cancer with fewer side effects
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
TWI796326B (zh) 2017-03-24 2023-03-21 日商第一三共股份有限公司 含有ａｘｌ抑制劑與ｅｇｆｒ酪胺酸激酶抑制藥的醫藥品及其用途
CN106883216B (zh) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法
CN108503627A (zh) * 2017-04-19 2018-09-07 郑州泰基鸿诺医药股份有限公司 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
CN106967050A (zh) * 2017-05-11 2017-07-21 北京工业大学 一种azd9291的制备方法
CN108929311B (zh) * 2017-05-22 2020-07-28 焦玉奇 2-(2,4,5-取代苯胺)嘧啶衍生物
WO2018214886A1 (zh) * 2017-05-24 2018-11-29 浙江同源康医药股份有限公司 一种氘代azd9291的晶型、制备方法及用途
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
KR102388312B1 (ko) * 2017-06-13 2022-04-19 베이징 아다메이들 바이오테크놀로지 리미티드 라이어빌리티 컴퍼니 아미노피리미딘 화합물, 이의 제조방법 및 용도
EP3638241B1 (en) 2017-06-16 2022-05-25 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
WO2019001425A1 (zh) * 2017-06-27 2019-01-03 浙江同源康医药股份有限公司 一种氘代奥斯替尼衍生物及其应用
CN107095873A (zh) * 2017-06-28 2017-08-29 卢凯华 具有低耐药性的抗肺癌靶向药物组合物
CN107216313B (zh) * 2017-06-29 2019-11-19 山东四环药业股份有限公司 一种抗肿瘤药物azd9291的制备方法
WO2019010619A1 (zh) * 2017-07-10 2019-01-17 焦玉奇 2-(2,4,5-取代苯胺)嘧啶衍生物
MY198379A (en) 2017-07-28 2023-08-28 Yuhan Corp Improved Process for Preparing Aminopyrimidine Derivatives
UA125595C2 (uk) 2017-07-28 2022-04-27 Юхан Корпорейшн Проміжні сполуки, корисні для синтезу селективного інгібітора щодо протеїнкінази, і способи їх отримання
CN107266426A (zh) * 2017-08-15 2017-10-20 南通因诺威医药科技有限公司 2‑氨烃基嘧啶类化合物及其制备方法和用途
EP3672633A1 (en) 2017-08-21 2020-07-01 Eli Lilly and Company Combinations of egfr inhibitors and anti-human vegfr-2 antibodies
CN109485638B (zh) * 2017-09-12 2020-07-17 新发药业有限公司 一种奥希替尼中间体的制备方法
CN107915725B (zh) * 2017-10-20 2023-06-27 复旦大学 Azd9291的药用盐及其制备方法
AU2018368453B2 (en) * 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
MY205589A (en) 2018-01-08 2024-10-28 G1 Therapeutics Inc G1t38 superior dosage regimes
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11202007256PA (en) 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
SG11202007492XA (en) * 2018-02-08 2020-09-29 Neupharma Inc Certain chemical entities, compositions, and methods
SG11202007414XA (en) 2018-02-12 2020-09-29 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
CA3087797A1 (en) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of egfr inhibitors and methods of use thereof
JP2021514398A (ja) * 2018-02-20 2021-06-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
CN108250187B (zh) * 2018-03-01 2021-01-05 中国科学院上海药物研究所 吲哚-1-碳酸酯类化合物、其制备方法和应用
CN108191861B (zh) * 2018-03-01 2020-10-02 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
CN109666024A (zh) * 2018-03-20 2019-04-23 兰州大学 2-氧嘧啶类化合物及其制备方法和用途
CN108218839A (zh) * 2018-03-20 2018-06-29 上药康丽（常州）药业有限公司 一种抗肿瘤药物azd9291的制备方法
CN108484579A (zh) * 2018-03-28 2018-09-04 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成奥希替尼中间体的方法
CN108530450B (zh) * 2018-05-03 2021-03-30 赖建智 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
US12084431B2 (en) 2018-05-14 2024-09-10 Takeda Pharmaceutical Company Limited Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
CN112119074A (zh) * 2018-05-15 2020-12-22 益方生物科技（上海）有限公司 Egfr抑制剂
CN110606842B (zh) * 2018-06-15 2021-06-01 上海艾力斯医药科技股份有限公司 吡啶胺基嘧啶衍生物的制备方法及其中间体
CN110698461B (zh) * 2018-07-09 2024-04-05 上海翰森生物医药科技有限公司 第三代egfr抑制剂的制备方法
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US12090153B2 (en) 2018-10-05 2024-09-17 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
CN109134435B (zh) * 2018-10-29 2023-01-03 湖南大学 一种奥希替尼azd9291的合成方法
CN111233774B (zh) * 2018-11-28 2023-04-14 鲁南制药集团股份有限公司 一种胺基嘧啶类化合物
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN113227073B (zh) * 2019-01-05 2022-09-16 山东轩竹医药科技有限公司 Egfr酪氨酸激酶的选择性抑制剂的盐及其晶型
CN111410651B (zh) * 2019-01-05 2021-06-04 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂的盐及其晶型
JP7577672B2 (ja) 2019-02-22 2024-11-05 ハンミ ファーマシューティカルズ カンパニー リミテッド Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
CN111606889B (zh) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
CN113773304B (zh) * 2019-02-25 2023-03-10 江苏豪森药业集团有限公司 抗耐药抗肿瘤egfr抑制剂的制备方法
CN109928956B (zh) * 2019-02-27 2020-10-13 杭州偶联医药科技有限公司 一种靶向泛素化降解egfr蛋白的化合物及其药物组合物和应用
WO2020192302A1 (zh) * 2019-03-27 2020-10-01 广州必贝特医药技术有限公司 含嘧啶的三取代咪唑类化合物及其应用
CN111747931A (zh) 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
AU2020250832A1 (en) 2019-03-29 2021-11-11 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
EA202100252A1 (ru) * 2019-04-09 2022-03-10 Хэнань Дженьюин Биотек Ко., Лтд. Производная 2-(2,4,5-замещенного фениламино)пиримидина и его кристаллическая форма "в"
CN109942550A (zh) * 2019-04-15 2019-06-28 广州医科大学附属第一医院（广州呼吸中心） 11c标记的egfr正电子示踪剂及其制备方法和应用
CN113784712A (zh) 2019-05-01 2021-12-10 克雷西奥生物科技有限公司 治疗瘙痒的方法
KR102898876B1 (ko) 2019-05-05 2025-12-12 제넨테크, 인크. Cdk 억제제
JP2022534063A (ja) * 2019-05-22 2022-07-27 上▲海▼翰森生物医▲薬▼科技有限公司 インドール誘導体含有阻害剤、そのための調製方法及びその用途
AU2020308814A1 (en) 2019-06-27 2022-02-03 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
CN110283162B (zh) * 2019-07-09 2022-04-05 辽宁大学 一种表皮生长因子受体抑制剂及其应用
CN110483486B (zh) * 2019-09-17 2024-01-26 鲁南制药集团股份有限公司 一种奥西替尼酮咯酸盐晶型及其制备方法
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021111462A1 (en) * 2019-12-02 2021-06-10 Natco Pharma Limited An improved process for the preparation of osimertinib mesylate
EP4076667A1 (en) 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN114980883A (zh) 2020-01-20 2022-08-30 阿斯利康(瑞典)有限公司 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
IL272441B (en) * 2020-02-03 2021-08-31 Ottek Ltd System and method for driving an endoscope
CN113372332B (zh) * 2020-03-10 2023-09-12 鲁南制药集团股份有限公司 一种奥希替尼新晶型
CN113372331B (zh) * 2020-03-10 2023-09-12 鲁南制药集团股份有限公司 一种奥希替尼一水合物新晶型
CN111303123B (zh) * 2020-03-31 2021-08-31 南京雷正医药科技有限公司 2-(2,4,5-取代苯胺基)嘧啶化合物及其应用
CN111285852A (zh) * 2020-04-02 2020-06-16 广州博济医药生物技术股份有限公司 氘代奥希替尼药用盐的晶型及其制备方法
CN111303124A (zh) * 2020-04-08 2020-06-19 北京赛思源生物医药技术有限公司 一种甲磺酸奥希替尼的新晶体
US20210369709A1 (en) * 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113801101A (zh) * 2020-06-15 2021-12-17 鲁南制药集团股份有限公司 Azd9291-2-酮戊二酸盐及其制备方法
CN113929663B (zh) * 2020-06-29 2025-06-17 鲁南制药集团股份有限公司 Azd9291-2-吲哚甲酸盐及其制备方法
CN113929664A (zh) * 2020-07-13 2022-01-14 鲁南制药集团股份有限公司 Azd9291-3,5-吡啶二羧酸盐及其制备方法
CN113968845A (zh) * 2020-07-24 2022-01-25 鲁南制药集团股份有限公司 Azd9291-没食子酸盐及其制备方法
US20230321098A1 (en) 2020-08-25 2023-10-12 Loxo Oncology, Inc. Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers
AU2021347232A1 (en) 2020-09-23 2023-04-27 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN112430231B (zh) * 2020-11-06 2022-09-30 德州德药制药有限公司 一种azd9291的工业化制备方法
CN112358468B (zh) * 2020-11-10 2022-03-22 德州德药制药有限公司 一种工业化合成azd9291的方法
TW202222795A (zh) * 2020-11-19 2022-06-16 大陸商上海翰森生物醫藥科技有限公司 一種含吲哚類衍生物的鹽、晶型及其製備方法和應用
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022265950A1 (en) 2021-06-15 2022-12-22 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
WO2023011505A1 (zh) * 2021-08-06 2023-02-09 上海和誉生物医药科技有限公司 嘧啶或吡啶衍生物及其制备方法和在药学上的应用
CA3229553A1 (en) 2021-09-02 2023-03-09 Synthon B.V. A process for making osimertinib
CN113683612B (zh) * 2021-09-07 2022-06-17 山东铂源药业股份有限公司 一种帕布昔利布的制备方法
JP7702205B2 (ja) * 2021-09-15 2025-07-03 株式会社東芝 新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去
CN116099006A (zh) * 2021-11-10 2023-05-12 上海交通大学医学院附属新华医院 奥西替尼及其药学上可接受的盐在制备急性髓细胞白血病药物中的应用
CN114014847B (zh) * 2021-12-08 2023-11-03 滨州医学院 一种含苯并噻吩嘧啶衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN114380806B (zh) * 2022-03-24 2022-06-10 中国药科大学 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用
AU2023246862A1 (en) 2022-03-31 2024-10-31 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
AR128999A1 (es) 2022-04-07 2024-07-03 Astrazeneca Ab Proceso mejorado para la fabricación de osimertinib
CA3249080A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
KR20250016160A (ko) * 2022-05-03 2025-02-03 도이체스 첸트룸 퓌어 노이로데게네라티페 에르크랑쿵겐 이. 브이. 타우 단백질 억제제
KR20250029133A (ko) 2022-06-27 2025-03-04 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN115650974B (zh) * 2022-08-04 2024-06-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用
EP4590662A1 (en) * 2022-09-19 2025-07-30 Advenchen Pharmaceuticals, LLC Novel pyrimidine compound as kinase inhibitors with biological activities on egfr mutants
CN116655601B (zh) * 2023-06-05 2025-08-29 河南应用技术职业学院 一种奥希替尼的合成方法
WO2025124936A1 (en) 2023-12-15 2025-06-19 Synthon B.V. A process for making osimertinib
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL144745A0 (en) 1999-02-10 2002-06-30 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
NZ522861A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
JP2004504391A (ja) 2000-07-07 2004-02-12 アンギオジェン・ファーマシューティカルズ・リミテッド 血管新生阻害剤としてのコルキノール誘導体
US6881737B2 (en) * 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP5132319B2 (ja) * 2004-12-21 2013-01-30 スミスクライン ビーチャム コーポレーション ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
MX2007009317A (es) 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
NZ594385A (en) 2005-11-03 2013-02-22 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
WO2007067506A2 (en) * 2005-12-05 2007-06-14 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
US20100267707A1 (en) 2006-06-22 2010-10-21 Merck Sharp & Dohme Corp. Tyrosine Kinase Inhibitors
JP2009544592A (ja) * 2006-07-21 2009-12-17 ノバルティス アクチエンゲゼルシャフト Ｊａｋキナーゼ阻害剤としての２，４−ジ（アリールアミノ）−ピリミジン−５−カルボキサミド化合物
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2214486A4 (en) 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) * 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2352827A4 (en) 2008-09-05 2016-07-20 Celgene Avilomics Res Inc ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
IN2012DN02534A (enExample) 2009-09-16 2015-08-28 Avila Therapeutics Inc
EP2496574A1 (en) * 2009-11-02 2012-09-12 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
US8957065B2 (en) 2010-06-23 2015-02-17 Hanmi Science Co., Ltd Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
AU2012250517B2 (en) * 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
DK3686194T3 (da) 2011-07-27 2021-11-22 Astrazeneca Ab 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser

Also Published As

Publication number Publication date
CN104109161B (zh) 2016-08-17
JP5537704B2 (ja) 2014-07-02
PL3686193T3 (pl) 2022-06-13
EA201391491A1 (ru) 2014-08-29
CA2882018C (en) 2017-04-25
EA201792394A2 (ru) 2018-03-30
US10858336B2 (en) 2020-12-08
IL242279A0 (en) 2015-11-30
CA2881993C (en) 2017-05-09
WO2013014448A1 (en) 2013-01-31
JP5427321B2 (ja) 2014-02-26
AU2012288626C1 (en) 2015-09-17
AR087336A1 (es) 2014-03-19
EA024421B1 (ru) 2016-09-30
ES2791308T3 (es) 2020-11-03
IL229199A0 (en) 2014-01-30
SI2736895T1 (sl) 2016-03-31
US20210130318A1 (en) 2021-05-06
US20150119379A1 (en) 2015-04-30
US9732058B2 (en) 2017-08-15
DOP2013000263A (es) 2014-01-31
UY34219A (es) 2013-02-28
ME02887B (me) 2018-04-20
HRP20211682T1 (hr) 2022-03-04
PT3333161T (pt) 2020-05-18
SMT202100652T1 (it) 2022-01-10
SI3333161T1 (sl) 2020-07-31
PT3686193T (pt) 2022-05-20
AU2012288626A8 (en) 2013-09-26
PH12013502312A1 (en) 2016-07-13
EP3686194B1 (en) 2021-09-15
CY1125405T1 (el) 2023-03-24
HK1256370A1 (en) 2019-09-20
AU2012288626A1 (en) 2013-05-02
DK2736895T3 (da) 2016-02-29
RS60190B1 (sr) 2020-06-30
EA201792394A3 (ru) 2018-07-31
PL3333161T3 (pl) 2020-08-24
TWI555743B (zh) 2016-11-01
BR112014001768A2 (pt) 2017-02-14
PL3686194T3 (pl) 2022-01-17
KR101410902B1 (ko) 2014-06-20
IL242286A0 (en) 2015-11-30
RS62542B1 (sr) 2021-12-31
US8946235B2 (en) 2015-02-03
CA2881993A1 (en) 2013-01-31
CN104109161A (zh) 2014-10-22
ES2900230T3 (es) 2022-03-16
SG10201402860QA (en) 2014-08-28
BR122014026094A2 (pt) 2019-08-20
ECSP13013033A (es) 2014-01-31
MY161925A (en) 2017-05-15
IL229199A (en) 2015-11-30
EA029488B1 (ru) 2018-04-30
PL2736895T3 (pl) 2016-05-31
CO6811863A2 (es) 2013-12-16
MX2014000528A (es) 2014-05-01
EP2736895B1 (en) 2016-01-06
CY1120072T1 (el) 2018-12-12
US20240425476A1 (en) 2024-12-26
CA2881991C (en) 2016-10-25
MX2020013020A (es) 2022-06-14
EA033733B1 (ru) 2019-11-20
EP3333161A1 (en) 2018-06-13
BR112014001768B1 (pt) 2019-02-05
IL242278A (en) 2016-12-29
SG10201910986QA (en) 2020-01-30
PH12015501326B1 (en) 2015-09-14
CR20130629A (es) 2014-03-12
PE20141700A1 (es) 2014-11-20
CL2013003281A1 (es) 2014-07-25
IL242279A (en) 2016-07-31
HK1221216A1 (en) 2017-05-26
BR122014026150B1 (pt) 2020-10-13
US10017493B2 (en) 2018-07-10
TW201319057A (zh) 2013-05-16
CN105198862A (zh) 2015-12-30
CN104109151A (zh) 2014-10-22
DK3009431T3 (en) 2018-01-08
HK1192554A1 (en) 2014-08-22
GT201300288A (es) 2017-10-09
IL242284A (en) 2016-07-31
CN105175396A (zh) 2015-12-23
HRP20171957T1 (hr) 2018-02-09
BR122014026150A2 (pt) 2019-05-28
HUE037645T2 (hu) 2018-09-28
ME02382B (me) 2016-06-20
CN105254616B (zh) 2017-10-17
ES2564671T3 (es) 2016-03-28
KR101422619B1 (ko) 2014-07-24
CN103702990B (zh) 2015-09-09
ES2914854T3 (es) 2022-06-17
EP3686194A1 (en) 2020-07-29
SG10201910984XA (en) 2020-01-30
HK1192549A1 (zh) 2014-08-22
PH12015501326A1 (en) 2015-09-14
EP3333161B1 (en) 2020-02-19
PL3009431T3 (pl) 2018-02-28
SI3009431T1 (en) 2018-01-31
US11524951B2 (en) 2022-12-13
IL242285A (en) 2016-07-31
EP3009431B1 (en) 2017-10-25
DK3686194T3 (da) 2021-11-22
LT3333161T (lt) 2020-05-11
JP2014094930A (ja) 2014-05-22
EP3686193A1 (en) 2020-07-29
AU2012288626B2 (en) 2015-05-07
US20130053409A1 (en) 2013-02-28
EP2736895A1 (en) 2014-06-04
CA2882018A1 (en) 2013-01-31
SI3686194T1 (sl) 2022-01-31
SG10201402857QA (en) 2014-08-28
PT3686194T (pt) 2021-11-11
HUE026429T2 (en) 2016-05-30
LT3009431T (lt) 2018-01-10
JP5977779B2 (ja) 2016-08-24
CA2843109A1 (en) 2013-01-31
CN105175396B (zh) 2018-01-16
IL242285A0 (en) 2015-11-30
TWI583386B (zh) 2017-05-21
CN103702990A (zh) 2014-04-02
ME03785B (me) 2021-04-20
US20190389834A1 (en) 2019-12-26
DK3686193T3 (da) 2022-05-30
RS56679B1 (sr) 2018-03-30
KR20140062181A (ko) 2014-05-22
BR122014026094B1 (pt) 2020-10-13
CA2881991A1 (en) 2013-01-31
SMT201600070B (it) 2016-04-29
RS54653B1 (sr) 2016-08-31
TW201700099A (zh) 2017-01-01
CA2843109C (en) 2015-06-16
US20180162832A1 (en) 2018-06-14
IL242278A0 (en) 2015-11-30
SG194783A1 (en) 2013-12-30
CA2881987A1 (en) 2013-01-31
TW201443040A (zh) 2014-11-16
DK3333161T3 (da) 2020-05-18
IL242286A (en) 2016-07-31
CY1117431T1 (el) 2017-04-26
NI201300134A (es) 2014-02-12
CN105348266A (zh) 2016-02-24
EP4086246A1 (en) 2022-11-09
TWI465445B (zh) 2014-12-21
MX377900B (es) 2025-03-10
CN105348266B (zh) 2018-04-10
SMT202000208T1 (it) 2020-05-08
JP2013544273A (ja) 2013-12-12
US20190092746A1 (en) 2019-03-28
EP4119551A1 (en) 2023-01-18
BR122014026114A2 (pt) 2019-08-20
HUE049060T2 (hu) 2020-08-28
EP3686193B1 (en) 2022-03-02
US20240182441A1 (en) 2024-06-06
LT3686194T (lt) 2021-11-25
EA201690328A1 (ru) 2016-11-30
MY194532A (en) 2022-11-30
IL242284A0 (en) 2015-11-30
KR20140030089A (ko) 2014-03-11
JP2014139226A (ja) 2014-07-31
KR101691268B1 (ko) 2016-12-29
HRP20200624T1 (hr) 2020-07-10
HRP20160135T1 (hr) 2016-03-11
NZ617393A (en) 2014-11-28
PT3009431T (pt) 2017-12-26
KR20140047741A (ko) 2014-04-22
EP3009431A1 (en) 2016-04-20
CN105198862B (zh) 2018-01-23
CY1123210T1 (el) 2021-10-29
CN104109151B (zh) 2017-04-12
CA2881987C (en) 2017-04-25
CN105254616A (zh) 2016-01-20
BR122014026114B1 (pt) 2021-01-12
HUE056365T2 (hu) 2022-02-28

Similar Documents

Publication Publication Date Title
ES2654177T3 (es) Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer
AU2013204962B2 (en) Polymorphic form of a mesylate salt of n-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
EA046985B1 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
HK1256370B (en) 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
EA036521B1 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
AU2015261672A1 (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
HK1221216B (en) 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
NZ617393B2 (en) 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer